ReviewNature reviews. Neurology2012
Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology.
Review in Nature reviews. Neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Antemortem network analysis of spreading pathology in autopsy-confirmed frontotemporal degeneration.Brain communications · 2023Article
- Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology.Neurobiology of aging · 2022Article
- Auditory Verb Generation Performance Patterns Dissociate Variants of Primary Progressive Aphasia.Frontiers in psychology · 2022Article
- Structural MRI Signatures in Genetic Presentations of the Frontotemporal Dementia/Motor Neuron Disease Spectrum.Neurology · 2021Article
- Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes.Journal of neurology, neurosurgery, and psychiatry · 2021Article
- Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits.Acta neuropathologica communications · 2021Article
- Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers.Neurobiology of aging · 2019Article
- FTD spectrum: Neuroimaging across the FTD spectrum.Progress in molecular biology and translational science · 2019Review
- Neuroimaging in aging and neurologic diseases.Handbook of clinical neurology · 2019Review
- Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family.Alzheimer's research & therapy · 2018Review
- Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration.Neurology · 2017Article
- Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration.Acta neuropathologica communications · 2017Article
- Emerging Diagnostic and Therapeutic Strategies for Tauopathies.Current neurology and neuroscience reports · 2017Review
- Imaging and fluid biomarkers in frontotemporal dementia.Nature reviews. Neurology · 2017Review
- Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: A study combining MRI and FDG-PET.Brain imaging and behavior · 2017Article
- Music Perception in Dementia.Journal of Alzheimer's disease : JAD · 2017Article
- Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.Molecular neurobiology · 2016Review
- Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD.European journal of nuclear medicine and molecular imaging · 2016Article
- Single-voxel (1)H spectroscopy in the human hippocampus at 3 T using the LASER sequence: characterization of neurochemical profile and reproducibility.NMR in biomedicine · 2015Article
- Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Frontotemporal lobar degeneration (FTLD) encompasses a group of diseases characterized by neuronal loss and gliosis of the frontal and temporal lobes. Almost all cases of FTLD can be classified into three categories on the basis of deposition of one of three abnormal proteins: the microtubule-associated protein tau, TAR DNA-binding protein 43, or fused in sarcoma. The specific diagnoses within each of these three categories are further differentiated by the distribution and morphological appearance of the protein-containing inclusions. Future treatments are likely to target these abnormal proteins; the clinical challenge, therefore, is to be able to predict molecular pathology during life. Clinical diagnosis alone has had variable success in helping to predict pathology, and is particularly poor in the diagnosis of behavioral variant frontotemporal dementia, which can be associated with all three abnormal proteins. Consequently, other biomarkers of disease are needed. This Review highlights how patterns of atrophy assessed on MRI demonstrate neuroanatomical signatures of the individual FTLD pathologies, independent of clinical phenotype. The roles of these patterns of atrophy as biomarkers of disease, and their potential to help predict pathology during life in patients with FTLD, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.